The double-strand break-free approach increased functional GATA2 alleles and improved the engraftment of edited blood stem cells in mice ...

Targeted lipid nanoparticles generate CAR NK cells in mice, showing activity against cancer and autoimmune liver disease ...

John Wichelt discusses Kindeva’s Bridgeton facility, supporting injectable programs from clinical development through ...

Piers Ingram discusses the resurgence of immunology, engineering-led drug discovery, and why faster clinical execution will shape the next generation of medicines ...

Thoughtful label design and digital tools can help participants with dyslexia find and access essential clinical trial ...

An RNA sequencing and machine learning screening platform identified an RNA-processing factor that reduced markers of ...

First-in-human study demonstrates the potential of rapidly manufactured trispecific CAR T cells to deliver durable remissions ...

Vyriad has begun a phase I trial of VV169, an off-the-shelf lentiviral therapy designed to generate BCMA-targeted CAR T cells directly inside the body. The first-in-human study is recruiting patients ...

Produced in partnership with IBTV, our Roving Reporter series captures real-time perspectives from across the life sciences industry. Filmed on the show floor at ASGCT 2026 in Boston, this episode ...

Regulators often argue, with some justification, that their statutory remit is quality, safety and efficacy – not price, reimbursement, or affordability. EMA, for example, states that it has no role ...

What was your biggest professional highlight of the past 12 months? When CCRM was established 15 years ago, we were very forward-thinking in recognizing biomanufacturing as a major gatekeeper of ...

Operational changes may be even more important than policy changes. One would be faster clinical trial approval and start-up. This is critical to accelerate evidence generation and enable project ...